Amneal Biosciences

Alymsys

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Amneal Biosciences

Alymsys HCPCS:

Q5126

HCPCS Code Descriptor:

Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg

Category:

Q Code

Alymsys NDCs:

70121-1754-01, 70121-1755-07, 70121-1754-07, 70121-1755-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Alymsys CPT Codes:

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have identified listing errors with the following NDCs:

70121-1754-07, 70121-1755-07

About Alymsys:

Alymsys is an Oncology drug manufactured by Amneal Biosciences and administered via the Intravenous route of administration. The Q Code: Q5126 is aligned to the drug Alymsys.

Alymsys is an artificial antibody (IgG1) that can be used to treat various types of cancer. This medication blocks the VEGF protein which decreases tumor growth rate. Alymys is manufactured by Amneal Biosciences and is a biosimilar to the medication Avastin (J9035). The HCPCS code for Alymsys is Q5126, this HCPCS code was aligned to the medication January 2023. It was previously aligned to the HCPCS code C9142 from October 2022 through December 2022. Patient assistance programs for Alymsys can be found through the Amneal Patient assistance program.

ACCESS PRICING AND MORE BY REGISTERING

Q5126 Added Date:

January 1, 2023

Q5126 Effective Date:

January 1, 2023

Q5126 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Alymsys billing and coding information.
Alymsys patient assistance information can be found through The Amneal Patient Assistance Program at the URL: https://www.amneal.com/about/responsibility/patient-assistance-programs/
Alymsys prescribing information can be found at the link below:
Information regarding Alymsys’s side effects can be found at MedlinePlus